Mesoblast (MESO) Total Debt (2018 - 2025)
Mesoblast (MESO) posted Total Debt of -$82.6 million for Q4 2025, down 136.01% sequentially from $229.3 million in Q2 2025, and down 116.89% YoY from $488.8 million in Q4 2024.
Mesoblast (MESO) Total Debt (2018 - 2025) Analysis & Trends
Mesoblast has reported Total Debt for 8 years, with the latest figure at -$82.6 million in Q4 2025.
- Quarterly Total Debt fell 116.89% year-over-year to -$82.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$82.6 million (down 116.89% YoY) and the FY2025 annual result came in at $229.3 million, up 100.52% from the prior year.
- Total Debt fell to -$82.6 million in Q4 2025 per MESO's latest filing, from $229.3 million in the prior quarter.
- Over five years, Total Debt peaked at $229.3 million in Q2 2025 and troughed at -$82.6 million in Q4 2025.
- A 5-year average of $76.1 million and a median of $94.2 million in 2021 frame the typical range for Total Debt.
- The sharpest annual moves came in 2022 and 2024: Total Debt jumped 341.66% in 2022, then slumped 141.53% in 2024.
- Over 5 years, Total Debt stood at $173.1 million in 2021, then plunged by 110.82% to -$18.7 million in 2022, then gained by 15.85% to -$15.8 million in 2023, then plunged by 141.53% to -$38.1 million in 2024, then slumped by 116.89% to -$82.6 million in 2025.
- According to Business Quant data, Total Debt over the past three periods registered -$82.6 million, $229.3 million, and -$38.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | -82.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -82.58 Mn |
| Jun 30, 2025 | 229.29 Mn |
| Dec 31, 2024 | -38.07 Mn |
| Jun 30, 2024 | 114.35 Mn |
| Dec 31, 2023 | -15.76 Mn |
| Jun 30, 2023 | 108.76 Mn |
| Mar 31, 2023 | -20.02 Mn |
| Dec 31, 2022 | -18.73 Mn |
| Sep 30, 2022 | 188.37 Mn |
| Jun 30, 2022 | 96.63 Mn |
| Mar 31, 2022 | 177.29 Mn |
| Dec 31, 2021 | 173.08 Mn |
| Sep 30, 2021 | 42.65 Mn |
| Jun 30, 2021 | 94.25 Mn |
| Mar 31, 2021 | 92.52 Mn |
| Dec 31, 2020 | 98.17 Mn |
| Sep 30, 2020 | 112.20 Mn |
| Jun 30, 2020 | 114.05 Mn |
| Mar 31, 2020 | 119.90 Mn |
| Dec 31, 2019 | 131.99 Mn |